ABRAXIS BIO (NASDAQ:ABII)
33.63
-0 (-0%)
| ABRAXIS BIO (NASDAQ:ABII) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $33.63 | 52 Week High | $74.50 | ||
| Open | $33.50 | 52 Week Low | $24.52 | ||
| Day High | $33.63 | P/E | N/A | ||
| Day Low | $33.63 | EPS | $-6.63 | ||
| Volume | 8,807 | ||||
| More ABII Info: Chart SEC Filings Profile Historical Options | |||||
Abraxis BioScience Summary
Abraxis Bioscience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses.
Executives
Patrick Soon-Shiong - Chairman, CEO
Links
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| CTIC | 2 | BMY | 1 |
| ATPG | 1 | CIA | 1 |
| EOG | 1 | GTSI | 1 |
| IPCC | 1 | LTRX | 1 |
| NFG | 1 | PLUG | 1 |
| SBUX | 1 | SXCI | 1 |
Entities who have mentioned ABII
- Merriman Curhan Ford | View Related Stories »
- Bankruptcy | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- 13D | View Related Stories »
- Lazard | View Related Stories »
- Twitter | View Related Stories »
- Carl Icahn | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- GLG Partners | View Related Stories »
- Trading Radar | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
View All ReportsStreetInsider.com Reports on ABII
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Merriman Curhan Ford Initiates Coverage on Abraxis BioScience (ABII) with a Buy
- Abraxis BioScience's (ABII) ABRAXANE Approved for Advanced Breast Cancer Patient Treatment in Quebec
- Abraxis BioScience (ABII) Files $400M Mixed Shelf, Up To 2M Shares For Shareholders
- Unusual 11 Mid-Day Movers 6/1: FEP, PMI, GPRE, ETWC Higher; ABIO, SNTA, ABII, EDZ Lower
View All Press ReleasesCompany Press Releases on ABII
- Abraxis BioScience Reports 2009 Third Quarter Financial Results
- ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
- Abraxis Health Dedicates State of the Art Nanotechnology & Biologics Facility in Phoenix, Arizona
- Trading Review for Cell Therapeutics Incorporated Issued by Beacon Equity
- Abraxis BioScience to Present at the Merriman Curhan Ford Investor Summit and Lazard Capital Markets Healthcare Conference
StreetInsider Reports on ABII by Category
View All BlogsBlogs on ABII
- Analyst upgrades, downgrades and initiations: CCL, CSX, EBAY, GLW, NFLX, YHOO ...
- Who Will Buy Spectrum Pharmacueticals?
- FDA Calendar Updates: BioMarin, OSI, Roche, Abraxis, Johnson & Johnson
- A Look at D.E. Shaw's Q408 Holdings: Just for Fun
- Abraxis BioScience, Inc., Q4 2008 Earnings Call Transcript
View All FilingsSEC Filings on ABII
- Form 4 Abraxis BioScience, Inc. For: Nov 10 Filed by: Wendel Bruce
- Form 10-Q Abraxis BioScience, Inc. For: Sep 30
- Form 8-K Abraxis BioScience, Inc. For: Nov 05
Comments on ABII
No comments are currently available.
